C
Cargene Biopharma
Oligonucleotide therapeutics for cardiovascular, fibrotic, and pulmonary diseases
About Cargene Biopharma
Cargene Biopharma is a preclinical-stage biopharmaceutical company founded in 2020, with operations in Singapore, the USA, and China. The company develops oligonucleotide therapeutics to treat a range of conditions, primarily focusing on cardiovascular, fibrotic, and pulmonary diseases, as well as ophthalmic disorders.
The company was co-founded by XQ Lin, the founder and Chairman of EVX Ventures; Dr. Yann Chong Tan, a serial biotech entrepreneur; and Dr. Torsten Wuestefeld, a principal investigator at A*STAR’s Genome Institute of Singapore. In June 2022, Kathy He, a veteran biopharmaceutical executive with over 20 years of experience, was appointed as CEO. Cargene's scientific advisory board includes world-class scientists such as Professors Harvey Lodish, Roger Foo, and Kausik Ray.
Cargene utilizes proprietary technology platforms, including the OSCAR™ algorithm and SMoP™ pharmacophore design, to create highly potent, specific, and stable small interfering RNAs (siRNAs). These platforms are aimed at addressing previously undruggable targets. One of its initial programs focuses on non-alcoholic steatohepatitis (NASH), using in-licensed technology from Singapore's Agency for Science, Technology and Research (A*STAR) to reduce liver fibrosis and enhance liver regeneration. The company is also developing technologies for targeted delivery of oligonucleotides to various tissues.
In December 2021, Cargene closed an oversubscribed pre-Series A funding round of $19.2 million. The financing was led by BioTrack Capital and included participation from Hyfinity Investments and Legendstar Capital. These funds are intended to advance the company's lead asset to an Investigational New Drug (IND) application and to further develop its technology platforms.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Singapore
- Employees
- 3
- Open positions
- None listed
- Dealroom signal
- 60.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Spinout, Techbio, DT and LS, science-based
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Dec 2021 | $19M | $77M | Hyfinity Investments · BioTrack Capital | ↗ |
| SPINOUT✓Other financing | Jan 2020 | $0 | — | A-STAR | — |
Growth signals
Latest recorded traffic for Cargene Biopharma is 590 monthly website visits, down 35.2% over the last three months. Cargene Biopharma's team declined 25% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Cargene Biopharma in its local ecosystem
The Cargene Biopharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
BioTrack Capital
Hyfinity Investments
Other known investors2 additional known investors
A-STAR- EVEVX Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cargene Biopharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cargene Biopharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









